Professor Nicholas Lintzeris has worked in the AOD sector for over 30 years in Australia and the UK as a clinician (addiction medicine specialist) and researcher (PhD). He has been at the forefront of medication development in opioid use disorder internationally, having led trials of methadone, buprenorphine, slow release morphine, LAAM, injectable opioids (including heroin and methadone), and take home naloxone. He has led a number of trials of long-acting depot buprenorphine in Australia, including current research into withdrawal off LADB, transfers from methadone to LADB and pain management with LADB. He established training programs re: LADB for health providers, and is lead author of the NSW Guidance on LADB.
Prof Nick Lintzeris
Director and Senior Staff Specialist, Drug and Alcohol Services, South East Sydney Local Health District (SESLHD), NSW Health; Conjoint Professor, Discipline of Addiction Medicine, Faculty Medicine and Health, University of Sydney
